Switch theme
Sign up to access all valuation multiples
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and XS00Y.
2003
27
LTM Revenue $3.4M
LTM EBITDA -$25.8M
$113M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
XSpray Pharma has a last 12-month revenue of $3.4M and a last 12-month EBITDA of -$25.8M.
In the most recent fiscal year, XSpray Pharma achieved revenue of n/a and an EBITDA of -$27.3M.
XSpray Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See XSpray Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$16.9M | -$27.3M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$13.1M | -$17.8M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, XSpray Pharma's stock price is SEK 33 (or $3).
XSpray Pharma has current market cap of SEK 1.2B (or $121M), and EV of SEK 1.1B (or $113M).
See XSpray Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $113M | $121M | XXX | XXX | XXX | XXX | $-0.72 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, XSpray Pharma has market cap of $121M and EV of $113M.
XSpray Pharma's trades at 32.9x LTM EV/Revenue multiple, and -4.4x LTM EBITDA.
Analysts estimate XSpray Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for XSpray Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $113M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -4.1x | XXX | XXX | XXX |
| P/E | -4.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -4.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpXSpray Pharma's NTM/LTM revenue growth is 1100%
XSpray Pharma's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.0M for the same period.
Over next 12 months, XSpray Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate XSpray Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for XSpray Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 62% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
XSpray Pharma acquired XXX companies to date.
Last acquisition by XSpray Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . XSpray Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was XSpray Pharma founded? | XSpray Pharma was founded in 2003. |
| Where is XSpray Pharma headquartered? | XSpray Pharma is headquartered in Sweden. |
| How many employees does XSpray Pharma have? | As of today, XSpray Pharma has 27 employees. |
| Who is the CEO of XSpray Pharma? | XSpray Pharma's CEO is Mr. Per Andersson. |
| Is XSpray Pharma publicy listed? | Yes, XSpray Pharma is a public company listed on STO. |
| What is the stock symbol of XSpray Pharma? | XSpray Pharma trades under XSPRAY ticker. |
| When did XSpray Pharma go public? | XSpray Pharma went public in 2017. |
| Who are competitors of XSpray Pharma? | Similar companies to XSpray Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of XSpray Pharma? | XSpray Pharma's current market cap is $121M |
| What is the current revenue of XSpray Pharma? | XSpray Pharma's last 12-month revenue is $3.4M. |
| What is the current EBITDA of XSpray Pharma? | XSpray Pharma's last 12-month EBITDA is -$25.8M. |
| What is the current EV/Revenue multiple of XSpray Pharma? | Current revenue multiple of XSpray Pharma is 32.9x. |
| What is the current EV/EBITDA multiple of XSpray Pharma? | Current EBITDA multiple of XSpray Pharma is -4.4x. |
| Is XSpray Pharma profitable? | Yes, XSpray Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
